Eric Topol on Nostr: We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in ...
We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in a 17, 500 participant randomized trial of a GLP-1 anti-obesity drug is a big deal and likely will change the reimbursement landscape (and further promote uptake)
Published at
2023-08-08 16:18:44Event JSON
{
"id": "0648f286e0779942617ca2457fb1e4884245a9320c0bbddf88fba853696687be",
"pubkey": "5077f486a3f2f72d07e0efd5cb00aa243734739327371edd92d5c63a7b7dfe53",
"created_at": 1691511524,
"kind": 1,
"tags": [
[
"proxy",
"https://mstdn.social/users/erictopol/statuses/110854899273465715",
"activitypub"
]
],
"content": "We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in a 17, 500 participant randomized trial of a GLP-1 anti-obesity drug is a big deal and likely will change the reimbursement landscape (and further promote uptake)\n\nhttps://media.mstdn.social/media_attachments/files/110/854/898/207/984/799/original/8ff691daaffdf4f0.webp\n\nhttps://media.mstdn.social/media_attachments/files/110/854/898/989/650/033/original/7e2452fd8c904b74.png",
"sig": "ece34e57ed09a90d49419075f62047a164e5732dfbd0cb757f5725ef98cae5627c7b8909fa0c58f087788d6fea758bbec2a84f8219aac46fe4043553d07413a4"
}
